Leaflet: information for the user
Zolmitriptán Flas Cinfa5 mgorally disintegrating tablets EFG
Read this leaflet carefully before you start taking this medicine,because it contains important information for you.
-Keep this leaflet, as you may need to read it again.
-If you have any questions, consult your doctor or pharmacist.
Zolmitriptán Flas Cinfa contains zolmitriptan and belongs to a group of medicines called triptans.
Zolmitriptán Flas Cinfa is used to treat migraine headache in adults aged 18 years and above.
Do not take Zolmitriptán Flas Cinfa
If you are unsure whether any of this applies to you, consult your doctor or pharmacist.
Warnings and Precautions
Consult your doctor or pharmacist before starting to take Zolmitriptán Flas Cinfa:
If you go to a hospital, inform the medical staff that you are taking Zolmitriptán Flas Cinfa.
Zolmitriptán Flas is not recommended for people under 18 years or over 65.
Like other migraine treatments, excessive use of Zolmitriptán Flas may cause daily headaches or worsening of your migraine headaches. Consult your doctor if you think this is the case. You may need to stop using Zolmitriptán Flas to correct the problem.
Other Medications and Zolmitriptán Flas Cinfa
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.This includes herbal remedies and medications you purchase without a prescription.
Especially, inform your doctor if you are taking any of the following medications:
Migraine Medications
Depression Medications
Other Medications
If you are using herbal remedies that contain St. John's Wort (Hypericum perforatum), it may be more likely that adverse effects of Zolmitriptán Flas will occur.
Taking Zolmitriptán Flas Cinfa with Food and Drinks
You can take Zolmitriptán Flas with or without food. This does not affect how Zolmitriptán Flas works.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, consult your doctor or pharmacist before using this medication.
Driving and Operating Machines
This medication, like migraine, can cause drowsiness. If you experience these effects, avoid driving or using machines as it may be hazardous.
During a migraine crisis, your reactions may be slower than usual. Take this into account when driving or using tools or machines.
Zolmitriptán Flas Cinfa contains aspartame
This medication contains 1.80 mg of aspartame in each tablet.
Aspartame contains a source of phenylalanine that may be harmful in cases of phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body is unable to eliminate it correctly.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
You can take Zolmitriptán Flas as soon as a migraine headache begins. You can also take it once a headache has started.
- The recommended dose is one tablet.
- You can take another tablet after two hours if the migraine persists or recurs within 24 hours.
If the tablets do not provide sufficient relief for your migraine, inform your doctor. Your doctor may increase the dose to 10 mg or change your treatment.
Do not use more than the dose prescribed.
Take the buccal tablet in the following way:
To avoid crushing the buccal tablet, do not press the blister (Figure 1).
Each blister contains six blisters, separated by perforations. Separate a blister following the perforated lines (Figure 2).
Remove the foil carefully, starting from the corner indicated "remove aluminum" (Figures 3 and 4).
Remove the buccal tablet with dry hands and place it on your tongue, where it will dissolve and be swallowed with saliva. You do not need to drink water to swallow your tablet (Figure 5).
If you take more Zolmitriptán Flas than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Some of the symptoms listed below may be part of the migraine itself.
Stop taking Zolmitriptán Flas Cinfa and contact your doctor immediately if you experience any of the following side effects:
Rare side effects (may affect up to 1 in 1,000 people):
Very rare side effects (may affect up to 1 in 10,000 people):
Other side effects that may occur:
Frequent side effects (may affect up to 1 in 10 people):
Infrequent side effects (may affect up to 1 in 100 people):
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not store above 86°F (30°C).
Store in the original packaging.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Zolmitriptán Flas Cinfa
Appearance of Zolmitriptán Flas Cinfa and content of the container
Zolmitriptán Flas Cinfa buccal dispersible tablets are white or almost white, with flat faces, rounded, and beveled edges.
It is presented in Alu/Alu blisters. Each container contains 2, 6, or 12 (6 x 2) buccal dispersible tablets.
Only some container sizes may be commercially marketed.
Other presentations
Zolmitriptán Flas Cinfa 2.5 mg buccal dispersible tablets: containers of 2, 6, or 12 (6 x 2) tablets.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) - Spain
Responsible for manufacturing
Neuraxpharm Pharmaceuticals, S.L.
Avda. Barcelona 69
08970 Sant Joan Despí
Barcelona – Spain
or
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) - Spain
Last review date of this leaflet: November 2020
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
You can access detailed and updated information on this medicine by scanning the QR code included in the leaflet and packaging with your smartphone. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/74386/P_74386.html
QR code to: https://cima.aemps.es/cima/dochtml/p/74386/P_74386.html
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.